Nitrous
Nitrous oxide is an atypical dissociative inhalant with the chemical formula N₂O. First identified by Joseph Priestly in 1772, its anesthetic properties were later discovered in the 19th century, earning it the name 'laughing gas' due to its euphoria and laughter-inducing effects. When inhaled, it produces rapid analgesia, mild sedation, and brief psychedelic dissociation.12 Widely used medically in surgery and dentistry, it is also commonly encountered recreationally through whipped cream chargers.12 Chronic abuse may cause neurological damage through vitamin B12 inactivation.2
Contents
Dosage & Duration
Dosage
Doses are commonly measured in whipped cream chargers; a single standard cartridge contains about 8 g of nitrous oxide and provides roughly one to three lungfuls of gas. One or two lungfuls is generally sufficient for a short experience, and a typical session involves 1-5 cartridges or balloons. Repeated use in quick succession should be avoided. Inhalation of pure nitrous oxide causes oxygen deprivation, which can lead to low blood pressure, fainting, and cardiac events, particularly with continuous inhalation from a mask or gas canister or with prolonged breath-holding. Non-medical formulations such as whipped-cream chargers contain no oxygen. Nitrous oxide is neurotoxic and can cause irreversible neurological damage; heavy single-session use (at or above 400 g, roughly 200 L of gas) or regular daily or weekly use has been associated with peripheral neuropathy including ataxia and paresthesia. Loss of gross and fine motor control, balance, and coordination is prominent, so users should be seated before onset to avoid falls and injury.
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Visual
Hallucinatory States
In comparison to other more classical dissociatives, hallucinations are particularly rare with nitrous but possible at high dosages.
Suppressions
Auditory
The auditory effects found with nitrous oxide, although simplistic, are famously known to be particularly intense and consistent in their manifestation when compared to other hallucinogens.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
The mechanism of action of nitrous oxide is not fully understood, but it directly modulates a broad range of ligand-gated ion channels.3 NMDA receptor antagonism appears to be its primary pharmacological action, with an approximate EC50 of 30-40% inhaled concentration in cultured hippocampal neurons; even at 80%, N2O acts only as a partial inhibitor.4 It moderately blocks β2-subunit-containing nicotinic acetylcholine receptors (with preference for α4β2 over α4β4), weakly inhibits AMPA, kainate, GABAC, and 5-HT3 receptors, and slightly potentiates GABAA and glycine receptors.3 It activates two-pore-domain potassium channels, particularly TREK-15, and weakly inhibits Cav3.2 low-voltage-activated calcium channels.6 The analgesic properties of N2O appear to involve the release of endogenous opioid peptides in the brainstem, which disinhibits descending noradrenergic neurons that modulate pain signaling at α2-adrenoceptors in the spinal cord7, and N2O has been reported to bind directly at opioid receptor sites. N2O may also influence nitric oxide signaling in the central nervous system.
Pharmacokinetics
Nitrous oxide has very low solubility in blood, with a blood/gas partition coefficient of 0.46, which provides rapid onset and equally rapid clearance once administration ceases.8 Predicted ADMET modeling indicates that N2O is not a substrate of major cytochrome P450 enzymes (CYP2C9, CYP2D6, CYP3A4) and has low CYP inhibitory promiscuity.
Tolerance
Harm Potential
Addiction & Dependence
Psychological
ModerateNitrous oxide has gained the nickname 'hippy-crack' due to its tendency toward compulsive redosing in some users. While uncommon, individuals with easy access to large quantities may use it many times daily.9 The substance is considered to have low to moderate abuse potential overall.
Physical
LowPhysical dependence with psychological symptoms is possible with continuous use. The substance does not produce a classical physical withdrawal syndrome9, though psychological dependence can develop in heavy users.
Toxicity
Heavy and frequent long-term use can cause serious neurological damage including subacute combined degeneration of the spinal cord10; occasional recreational use at typical doses carries minimal risk, while chronic daily or weekly use significantly increases the likelihood of peripheral neuropathy.
Chronic heavy use can cause megaloblastic changes10 and, in severe cases, agranulocytosis; these effects are associated with prolonged B12 inactivation rather than occasional use.
Hypoxia from improper use can cause low blood pressure, fainting, and cardiac arrhythmia; serious cardiac events are rare and typically associated with pre-existing conditions or continuous inhalation without oxygen.
High-pressure administration directly from tanks can rupture blood vessels in the lungs and cause pneumothorax; this risk is eliminated by releasing gas into a balloon first.
Direct inhalation from tanks or whippits can cause frostbite to the lips, throat, larynx11, and bronchi due to extremely cold gas temperatures.
Psychosis Risk
Psychological issues including personality changes, mood disorders, psychosis, and hallucinations can occur10, primarily in the context of chronic heavy use and associated B12 deficiency rather than acute intoxication.
Seizure Risk
A short period of slight hypoxia from nitrous oxide use could potentially raise the chance of seizure in some users. Persons suffering from epilepsy are advised not to consume nitrous oxide.
History & Culture
Discovery and Early Research
Nitrous oxide was first synthesized in 1772 by English natural philosopher and chemist Joseph Priestley, who initially called it "dephlogisticated nitrous air."13 He produced the gas by heating iron filings dampened with nitric acid and passing the…
Legality
International
World Health Organization's List of Essential Medicines
By Country
References
Citations
- Kayla Knuf, & Christopher V. Maani. (2023-08-28). Nitrous Oxide. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK532922/12
- World Health Organization. (2023). Nitrous oxide: Critical Review Report. 46th Expert Committee on Drug Dependence, 1-40. https://cdn.who.int/media/docs/default-source/46th-ecdd/nitrous-oxide_46th-ecdd_critical-review_public-version.pdf123
- Tomohiro Yamakura, & R. Adron Harris. (2000). Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology, 93(4), 1095–1101. https://doi.org/10.1097/00000542-200010000-0003412345678910
- Michael C. Kalmoe, Amanda M. Janski, Charles F. Zorumski, Peter Nagele, Ben Julian A. Palanca, & Charles R. Conway. (2020). Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents. Journal of the Neurological Sciences, 412, Article 116778. https://doi.org/10.1016/j.jns.2020.1167781234567891011
- Marco Gruss, Trevor J. Bushell, Damian P. Bright, William R. Lieb, Alistair Mathie, & Nicholas P. Franks. (2004). Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Molecular Pharmacology, 65(2), 443–452. https://doi.org/10.1124/mol.65.2.44312
- P. Orestes, D. Bojadzic, J. Lee, E. Leach, R. Salajegheh, M. R. Digruccio, M. T. Nelson, & S. M. Todorovic. (2011). Free radical signalling underlies inhibition of CaV3.2 T-type calcium channels by nitrous oxide in the pain pathway. The Journal of Physiology, 589(1), 135–148. https://doi.org/10.1113/jphysiol.2010.196220123
- C. Zhang, K. L. Davies, T. G. Guo, & R. M. Maze. (1999). The analgesic action of nitrous oxide is dependent on the release of norepinephrine in the dorsal horn of the spinal cord. Anesthesiology, 91(5), 1401–1407. https://doi.org/10.1097/00000542-199911000-000331
- Daniel E. Becker, & Morton Rosenberg. (2008). Nitrous Oxide and the Inhalation Anesthetics. Anesthesia Progress, 55(4), 124–131. https://doi.org/10.2344/0003-3006-55.4.1241
- Tibor M Brunt, Wim van den Brink, & Jan van Amsterdam. (2022). Mechanisms Involved in the Neurotoxicity and Abuse Liability of Nitrous Oxide: A Narrative Review. International Journal of Molecular Sciences, 23(23), Article 14747. https://doi.org/10.3390/ijms23231474712
- Cyrille De Halleux, & David N. Juurlink. (2023). Diagnosis and management of toxicity associated with the recreational use of nitrous oxide. CMAJ, 195(32), E1075–E1081. https://doi.org/10.1503/cmaj.2301961234567
- Nosaiba K Ezzelarab, & Tarek Matar. (2025). Recreational Nitrous Oxide Misuse: Anaesthetic Challenges and Perioperative Complications Including Airway Burns and Neurological Sequelae. Cureus, 17(8), Article e89232. https://doi.org/10.7759/cureus.8923212
- Teresa Wrońska-Nofer, Jadwiga Palus, Wojciech Krajewski, Jolanta Jajte, Małgorzata Kucharska, Jan Stetkiewicz, Wojciech Wąsowicz, & Konrad Rydzyński. (2009). DNA damage induced by nitrous oxide: study in medical personnel of operating rooms. Mutation Research, 666(1–2), 39–43. https://doi.org/10.1016/j.mrfmmm.2009.03.0121
- Mark A. Gillman. (2019). Mini-Review: A Brief History of Nitrous Oxide (N2O) Use in Neuropsychiatry. Current Drug Abuse Reviews, 11(1), 12-20. https://doi.org/10.2174/187447371166618100816310712
- Humphry Davy. (1800). Researches, Chemical and Philosophical; Chiefly Concerning Nitrous Oxide, or Diphlogisticated Nitrous Air, and Its Respiration. J. Johnson. http://archive.org/details/researcheschemic00davy1
- Abderrahim Oussalah, Mélissa Julien, Julien Levy, & Jean-Louis Guéant. (2019). Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis. Journal of Clinical Medicine, 8(4), Article 551. https://doi.org/10.3390/jcm80405511234
- Home Office. (2014). Drug Misuse: Findings from the 2013 to 2014 Crime Survey for England and Wales. UK Home Office. https://www.gov.uk/government/statistics/drug-misuse-findings-from-the-2013-to-2014-csew/drug-misuse-findings-from-the-201314-crime-survey-for-england-and-wales1
- (n.d.). What is Galaxy Gas?. Poison Control. https://www.poison.org/articles/galaxy-gas1
- (n.d.). Rezeptpflichtverordnung, Annex 1. ris.bka.gv.at. https://ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Anlage=1&Artikel=&FassungVom=2026-04-23&Gesetzesnummer=10010358&Paragraf=&Uebergangsrecht=1
- (n.d.). Food and Drug Regulations, C.R.C., c. 870. laws-lois.justice.gc.ca. https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._870/page-50.html1
- (n.d.). Forskrift om omsetning og innførsel av produkter med lystgass, FOR-2026-03-05-340. lovdata.no. https://lovdata.no/dokument/LTI/forskrift/2026-03-05-3401
- (n.d.). Misuse of Drugs Act 1973, Fifth Schedule. sso.agc.gov.sg. https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc5-1
- (n.d.). Lag (2025:621) om lustgas. folkhalsomyndigheten.se. https://www.folkhalsomyndigheten.se/lustgas1
- (n.d.). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 360ddd–360ddd-1; 21 C.F.R. §§ 201.161, 184.1545. uscode.house.gov. https://uscode.house.gov/view.xhtml?edition=prelim&num=0&req=granuleid%3AUSC-prelim-title21-section360ddd1
- (n.d.). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 360ddd–360ddd-1; 21 C.F.R. §§ 201.161, 184.1545. ecfr.gov. https://www.ecfr.gov/current/title-21/part-184/section-184.15451
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Nitrous article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.